- Home
- Publications
- Publication Search
- Publication Details
Title
Systems approach to rational combination therapy: PARP inhibitors
Authors
Keywords
-
Journal
BIOCHEMICAL SOCIETY TRANSACTIONS
Volume -, Issue -, Pages -
Publisher
Portland Press Ltd.
Online
2020-05-07
DOI
10.1042/bst20191092
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer
- (2020) Daniel J. McGrail et al. CANCER CELL
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
- (2019) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- ADP-ribosylation and intracellular traffic: an emerging role for PARP enzymes
- (2019) Giovanna Grimaldi et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- A decade of clinical development of PARP inhibitors in perspective
- (2019) J Mateo et al. ANNALS OF ONCOLOGY
- Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
- (2019) Yong Fang et al. CANCER CELL
- Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options
- (2019) Marilyne Labrie et al. Oncotarget
- Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation
- (2019) Shuai Wang et al. Nature Chemical Biology
- WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer
- (2019) Andrea Sand et al. CANCER LETTERS
- BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
- (2018) Chaoyang Sun et al. CANCER CELL
- The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer
- (2018) Alice Lallo et al. CLINICAL CANCER RESEARCH
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
- (2017) Chaoyang Sun et al. Science Translational Medicine
- Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer
- (2016) U.A. Matulonis et al. ANNALS OF ONCOLOGY
- Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
- (2016) Hui Zhang et al. CELL
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
- (2014) D. Karnak et al. CLINICAL CANCER RESEARCH
- Mechanism-based cancer therapy: resistance to therapy, therapy for resistance
- (2014) P Ramos et al. ONCOGENE
- A pan-cancer proteomic perspective on The Cancer Genome Atlas
- (2014) Rehan Akbani et al. Nature Communications
- Insights into the regulation of protein abundance from proteomic and transcriptomic analyses
- (2012) Christine Vogel et al. NATURE REVIEWS GENETICS
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started